IGC Pharma develops drug candidates for Alzheimer's disease, with its lead candidate in clinical trials for agitation linked to the condition. IGC reports earnings on Fri, Nov 13, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 26 | Ascendiant Capital | Target raised | Buy | |
| Jun 8 | Ascendiant Capital | Maintained | Buy |
Whale Options Flow
90DNo whale options trades in IGC in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IGC is in one of them and how their past IGC trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered IGC in an article yet. Here's the latest on the wider market.
About IGC Pharma
IGC Pharma is a drug development company based in Potomac, Maryland, focused mainly on Alzheimer's disease. Its lead candidate, IGC-AD1, is in a clinical trial for agitation, a behavioral symptom common in people with Alzheimer's dementia. The company is also building MINT-AD, an artificial intelligence data tool meant to support clinicians and researchers in assessing risk in Alzheimer's patients. It does not yet sell pharmaceutical products.
- Headquarters
- Potomac, MD